臨床眼科77巻12号

2023年11月発行

特集 意外と知らない小児の視力低下

近視進行抑制治療をひも解く

著者： 木下望¹²

所属機関： ¹自治医科大学附属さいたま医療センター眼科 ²日本オルソケラトロジーと特殊コンタクトレンズ研究会（SOS-J）

ページ範囲：P.1439 - P.1446

●強度近視になると，眼軸長の伸展によりさまざまな眼疾患の発症リスクが高まる。

●小児の近視は年齢が低いほど進行が速いので，幼少期からの治療が重要である。

●近視進行抑制治療の発展により，近視を矯正する時代から抑制する時代へ移行した。

参考文献

1）Dolgin E：The myopia boom. Nature 519：276-278, 2015

2）Holden BA, Fricke TR, Wilson DA et al：Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123：1036-1042, 2016

3）Flitcroft DI：The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res 31：622-660, 2012

4）Chua WH, Balakrishnan V, Chan YH et al：Atropine for the treatment of childhood myopia. Ophthalmology 113：2285-2291, 2006

5）Chia A, Lu QS, Tan D：Five-year clinical trial on atropine for the treatment of myopia 2 myopia control with atropine 0.01％ eyedrops. Ophthalmology 123：391-399, 2016

6）Yam JC, Jiang Y, Tang SM et al：Low-concentration atropine for myopia progression（LAMP）study：a randomized, double-blinded, placebo-controlled trial of 0.05％, 0.025％, and 0.01％ atropine eye drops in myopia control. Ophthalmology 126：113-124, 2019

7）Yam JC, Zhang XJ, Zhang Y et al：Three-year clinical trial of low-concentration atropine for myopia progression（LAMP）study：continued versus washout：phase 3 report. Ophthalmology 129：308-321, 2022

8）Hieda O, Hiraoka T, Fujikado T et al：Efficacy and safety of 0.01％ atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol 65：315-325, 2021

9）Li SM, Kang MT, Wu SS et al：Efficacy, Safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Curr Eye Res 41：600-608, 2016

10）木下　望：近視から子どもたちの目を守れ！近視と闘い続けた眼科医からのメッセージ．72，132-133，幻冬舎，東京，2021

11）Chamberlain P, Peixoto-de-Matos SC, Logan NS et al：A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci 96：556-567, 2019

12）Sankaridurg P, Bakaraju RC, Naduvilath T et al：Myopia control with novel central and peripheral plus contact lenses and extended depth of focus contact lenses：2 year results from a randomised clinical trial. Ophthalmic Physiol Opt 39：294-307, 2019

13）Walline JJ, Walker MK, Mutti DO et al：Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children The BLINK randomized clinical trial. JAMA 324：571-580, 2020

14）Lam CSY, Tang WC, Tse DY et al：Defocus incorporated multiple segments（DIMS）spectacle lenses slow myopia progression：a 2-year randomised clinical trial. Br J Ophthalmol 104：363-368, 2020

15）Gwiazda J, Hyman L, Hussein M et al：A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci 44：1492-1500, 2003

16）Kinoshita N, Konno Y, Hamada N et al：Efficacy of combined orthokeratology and 0.01％ atropine solution for slowing axial elongation in children with myopia：a 2-year randomised trial. Sci Rep 10：12750, 2020

17）Hiraoka T, Kakita T, Okamoto F et al：Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia：a 5-year follow-up study. Invest Ophthalmol Vis Sci 53：3913-3919, 2012

18）Tan Q, Ng AL, Choy BN et al：One-year results of 0.01％ atropine with orthokeratology（AOK）study：a randomised clinical trial. Ophthalmic Physiol Opt 40：557-566, 2020

19）Guo BY, Cheung SW, Kojima R et al：One-year results of the Variation of Orthokeratology Lens Treatment Zone（VOLTZ）Study：a prospective randomised clinical trial. Ophthalmic Physiol Opt 41：702-714, 2021